Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
about
Androgen actions on endothelium functions and cardiovascular diseasesThe lived experience of physically active older prostate cancer survivors on androgen deprivation therapy.Can alternative medicine do better than placebo?: Does it even matter?No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.Update on the management of prostate cancer with goserelin acetate: patient perspectivesIntervening on the side effects of hormone-dependent cancer treatment: the role of strength training.Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancerAndrogen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanismRisk stratification in the hormonal treatment of patients with prostate cancerAn update on the changing indications for androgen deprivation therapy for prostate cancer.Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancerNutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: a study protocolCurrent nutrition promotion, beliefs and barriers among cancer nurses in Australia and New ZealandActing on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPERSupraventricular tachycardia and urticaria complicating leuprolide-induced ovarian suppression in a young woman with breast cancer: a case report.Testosterone and cardiovascular disease in men.Update on the safety of testosterone therapy in cardiac disease.Clinical exercise interventions in prostate cancer patients--a systematic review of randomized controlled trials.Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis.Challenges of managing elderly men with prostate cancer.Metformin and Prostate Cancer: a New Role for an Old Drug.The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients.Promotion and support of physical activity among cancer survivors: a service provider perspective.Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice.Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study.Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignanciesRandomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists.Perceived barriers and facilitators to physical activity in men with prostate cancer: possible influence of androgen deprivation therapy.Robotic radical prostatectomy as the initial step in multimodal therapy for men with high-risk localised prostate cancer: initial experience of 160 men.Early life exposure to the 1918 influenza pandemic and old-age mortality by cause of deathRole of androgens in cardiovascular pathologyWhat does the research say about androgen use and cerebrovascular events?
P2860
Q26750657-A054A86C-BC17-40CC-93FC-5758CD52465AQ30352157-22EA0DEB-C263-46DF-8473-780472308B4CQ33613065-F816CFB5-8060-4EFE-BEDE-EF262FC9C63DQ33897252-5420B537-DE10-4C7E-9867-3BEDC08768D9Q34418403-2AC38CC7-2BAB-4843-B775-18511449B1C7Q34557490-FB3EB1DF-907B-46A0-8414-DB6101D2FDC9Q34617904-125E145C-B9DC-45F5-92E4-D7BA367A60E0Q34784556-A26F2054-8C3F-47E4-97A0-6DF6FA57DAF8Q35076189-27FB1A2D-7D87-431E-8BED-E03355F3785EQ35549863-44AE0A7F-DAEF-4760-BB2E-C71A4FD311EBQ35865808-E44542C3-08A4-402D-A889-7925741FD345Q36238990-FFF70F9F-4D63-4C26-8C2D-A5623E1D4839Q36286887-DE5D4005-5353-4B46-8877-56D5D44B4202Q36800401-3D563158-7D4D-4C6E-8FD9-57EA8CF56872Q37037100-9A8493DE-92C6-40CC-943D-5798917BDD1DQ37037827-5BE84F7D-6AE2-4E90-8F05-540F98FA7CC3Q37854750-86DCF698-E27C-483D-8AE1-4DD381BAE261Q37944489-FBB11FA8-9C52-4212-95EA-7756199BFB7FQ38174997-8BCB33C0-5B4B-4A6A-A6D8-129BCEFF48ACQ38211358-608D98B0-97BB-47C8-A046-6E724D305B3AQ38819039-1A6E1ABF-62CE-490B-9B77-EDC2A3B1598EQ39032205-4D3200B5-CD4C-489D-BF10-1D723B289740Q39666514-41D8F368-852F-41A6-B707-636010FC5F7AQ41869871-FCB82E47-3596-4E51-8AD2-7138E52EC9D8Q42290613-92925FB8-28E7-46C5-9FCF-67914DA45EDBQ42578251-A6048EA4-DB5D-48DA-B0DF-87A54FED98BAQ42755574-D91E3FD8-7547-4675-9E44-099D4FCE6BAFQ47839361-CD3949C8-FB2F-4E10-9DF4-61253BA87514Q51521214-570BC484-2164-4706-AB1D-C8661278F5E7Q57099919-D322490F-6D12-464D-8548-CB637DC6ACF3Q58566481-069042CD-8C29-4917-B66A-7F5A9D9D7A57Q58574549-798DC287-2610-4412-8C07-3A482AF705D5
P2860
Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Increased risk of metabolic sy ...... n therapy for prostate cancer.
@en
Increased risk of metabolic sy ...... n therapy for prostate cancer.
@nl
type
label
Increased risk of metabolic sy ...... n therapy for prostate cancer.
@en
Increased risk of metabolic sy ...... n therapy for prostate cancer.
@nl
prefLabel
Increased risk of metabolic sy ...... n therapy for prostate cancer.
@en
Increased risk of metabolic sy ...... n therapy for prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Increased risk of metabolic sy ...... n therapy for prostate cancer.
@en
P2093
Lisa M Schultz
Polly E Kintzel
Sandra L Chase
Timothy J O'Rourke
P2860
P304
P356
10.1592/PHCO.28.12.1511
P407
P577
2008-12-01T00:00:00Z